Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)

NCT00557791 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study never initiated

Conditions

Age Related Macular Degeneration

Interventions

DRUG: Bevasiranib
DRUG: ranibizumab

Sponsor

OPKO Health, Inc.